GlassScriptPhysician profile
Stephanie A Clapper
NPI 1578718730
$8,775.88
in general payments reported to CMS, 2019-2025
45 companies · $1,934 in 2025
The $1,934 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $809 · 2020: $1,045 · 2021: $1,116 · 2022: $933 · 2023: $1,353 · 2024: $1,586 · 2025: $1,934.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,841 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,840.65 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,559.17 | 2020-2025 | Ubrelvy, Vraylar, Qulipta |
| Pfizer INC. | $997.50 | 2019-2025 | |
| Novo Nordisk INC | $841.73 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $787.03 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $689.20 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $492.85 | 2019-2025 | Otezla, Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $341.92 | 2019-2024 | Xarelto, Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $317.14 | 2023-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $252.85 | 2019-2025 | Trintellix |
| Amarin Pharma, INC. | $234.62 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $226.91 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $212.22 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $202.90 | 2022-2025 | Rexulti, Nuedexta |
| Allergan, INC. | $149.96 | 2019-2020 | |
| Axsome Therapeutics, INC. | $143.03 | 2022-2025 | Auvelity |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $139.49 | 2019-2024 | Veozah |
| Biohaven Pharmaceuticals, INC. | $97.77 | 2020-2021 | |
| Phathom Pharmaceuticals, INC. | $87.36 | 2024-2025 | Voquezna |
| Lundbeck LLC | $78.24 | 2024 | Rexulti |
| Esperion Therapeutics, INC. | $77.84 | 2020-2025 | Nexletol |
| Lilly USA, LLC | $77.12 | 2022-2025 | Jardiance, Reyvow, Emgality |
| Merck Sharp & Dohme LLC | $73.95 | 2021-2023 | Vaxelis, M-M-R II, Gardasil 9 |
| Novartis Pharmaceuticals Corporation | $72.93 | 2023-2024 | |
| Corium, LLC | $62.85 | 2025 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $55.14 | 2019-2022 | |
| Daiichi Sankyo INC. | $45.84 | 2024 | Injectafer |
| Insulet Corporation | $42.93 | 2024 | Omnipod |
| Sanofi-Aventis U.S. LLC | $39.84 | 2019-2024 | |
| Biogen, INC. | $35.26 | 2025 | Zurzuvae |
| Boston Scientific Corporation | $34.69 | 2025 | Watchman |
| Almatica Pharma LLC | $33.78 | 2021 | |
| Vyne Pharmaceuticals INC. | $30.82 | 2020 | |
| Nestle Healthcare Nutrition INC. | $27.50 | 2020 | |
| Bausch Health US, LLC | $22.28 | 2019 | |
| Abbott Laboratories | $21.50 | 2025 | Freestyle Libre 3 |
| Ibsa Pharma INC. | $20.76 | 2024 | Tirosint, Licart |
| Ucb, INC. | $20.27 | 2023 | Nayzilam |
| Axonics, INC. | $19.12 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.30 | 2019 | |
| Mannkind Corporation | $17.14 | 2019 | |
| Assertio Therapeutics, INC. | $17.03 | 2020 | |
| Genentech USA, INC. | $15.24 | 2020 | |
| Inspire Medical Systems, INC. | $14.99 | 2025 | Inspire |
| Renalytix Ai, INC. | $13.80 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
| Exact Sciences Corporation | $13.07 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Clapper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.